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In Brief Glassman, Parrish et al. use functional and biophysical assays to demonstrate that CD4 stabilizes TCR-pMHCII interactions via membrane distal and proximal domains. The data indicate that CD4 docks along a composite surface created by the TCR-CD3-pMHCII axis to confer a uniform macrocomplex architecture upon a diverse TCR repertoire.
INTRODUCTION

CD4
+ T cells are remarkable for their sensitivity, specificity, and the range of effector types to which a naive cell can differentiate after detecting a threat (i.e., helper [Th] , T follicular helper [Tfh] , regulatory [Treg] , and memory [Tm] ) (Zhu et al., 2010) . The quantity and quality of signals generated by the T cell receptor (TCR) are key determinants for CD4 + T cell development, activation, differentiation, and effector cell responses (Allison et al., 2016; Corse et al., 2010; Fazilleau et al., 2009; Gottschalk et al., 2010; Hwang et al., 2015; Savage et al., 1999; Stepanek et al., 2014; Tubo et al., 2013; van Panhuys et al., 2014; Vanguri et al., 2013) . But the genesis of these signals remains unclear because the relationship between the TCR and CD4 remains mechanistically undefined.
Each clonotypic TCR provides a CD4 + T cell with specificity for a limited number of peptides presented within class II major histocompatibility complex (pMHCII) molecules on antigen-presenting cells (APCs). The time a TCR spends confined to a pMHCII informs CD4 + T cell responsiveness. For interactions with slow on-rates, such that newly dissociated TCRs and pMHCII diffuse away from each other before rebinding, this equates to their t 1/2 ; however, for TCRs with on-rates that allow rebinding, responsiveness best relates to the aggregate t 1/2 (t a ) that considers rebinding as part of a total confinement time (Govern et al., 2010; Tubo et al., 2013; Vanguri et al., 2013) . TCR-pMHCII interactions relay information to the immunoreceptor tyrosine-based activation motifs (ITAMs) of the associated CD3gε, CD3dε, and CD3zz signaling modules (Gil et al., 2002; Lee et al., 2015) ; however, transmitting information across the membrane to the ten ITAMs within a TCR-CD3 complex (one per CD3g, d, and ε subunit, and three per z) is insufficient to generate chemical signals because the complex itself lacks intrinsic kinase activity. Rather, the Src kinase p56 Lck (Lck), which non-covalently associates with CD4, primarily phosphorylates the ITAMs (Malissen and Bongrand, 2015) . CD4 is critical for TCR-CD3 signaling to single agonist pMHCII, increases functional responses by 10-to 1,000+-fold and determines how a T cell perceives the potency of a pMHCII (Glaichenhaus et al., 1991; Irvine et al., 2002; Killeen and Littman, 1993; Parrish et al., 2016; Stepanek et al., 2014; Vidal et al., 1999) . When a CD4 molecule associated with Lck binds the same pMHCII as a TCR, it is thought to recruit Lck to phosphorylate the ITAMs (Malissen and Bongrand, 2015) . In this scenario, CD4 is a constant, binding to a monomorphic region of MHCII regardless of the nature of the peptide embedded therein, and thus regardless of whether or not the TCR is bound to the pMHCII.
But three pieces of evidence raise questions about how, upon TCR-pMHCII engagement, CD4 positions Lck and the ITAMs in a sufficient local concentration for a sufficient duration for phosphorylation to occur; particularly for the weak interactions that drive positive selection and peripheral homeostasis Kao and Allen, 2005; Stepanek et al., 2014; Wang et al., 2001b; Zuñ iga-Pfl€ ucker et al., 1989) . First, crystallography data suggest that the TCR-CD3 complex, pMHCII, and CD4 adopt a V-like arch that could place the CD3 ITAMs, and, in particular, the six ITAMs of zz, $100Å from a CD4-associated Lck (Wang et al., 2001a; Yin et al., 2012) . Second, interactions between the CD4 D1 domain and MHCII at the apex of this arch are too weak to measure in solution, and 2D affinity estimates suggest that CD4-MHCII interactions are $2-3 orders of magnitude weaker than TCR-pMHCII interactions (Hong et al., 2015; Jö nsson et al., 2016) . Finally, C-terminally truncated CD4 molecules that lack the cysteine clasp, and cannot directly interact with Lck, nevertheless increase TCR-CD3 signaling (Killeen and Littman, 1993; Parrish et al., 2016; Vidal et al., 1999) . A unifying understanding of how the TCR-CD3 complex, pMHCII, and CD4 fit and work together thus remains elusive.
Here, we tested predictions made by a V-like macrocomplex versus a more compact architecture in which CD4 docks along a composite surface formed by the TCR-CD3-pMHCII axis (Figure S1A) Kuhns and Badgandi, 2012; Wang et al., 2001a; Yin et al., 2012) . In the latter model, TCR-CD3 dwell time on pMHCII would determine the duration with which the CD4 docking site is formed and thus influence CD4 dwell time within a mature macrocomplex. In turn, CD4 docking would extend the TCR-CD3 dwell time on pMHCII. Neither would occur in the V-like arch since TCR-pMHCII and CD4-MHCII interactions are independent of one another. Finally, in the V-like arch CD4 binds MHCII only via the D1 domain, while CD4 would use its length to contact the TCR-CD3-pMHCII axis in a compact macrocomplex. To test these predictions, we varied the duration of TCR-pMHCII interactions with defined altered peptide ligands (APLs), and the duration of CD4-MHCII interactions with a CD4 D1 domain mutant, to study how these changes influenced the interplay between the TCR-CD3 complex and CD4 upon binding pMHCII. We also made mutants in the CD4 D3 domain. The data suggest that reciprocal interactions between the TCR-CD3 complex and CD4 ectodomains around a nucleating pMHCII impact the assembly, stability, and function of the TCR-CD3-pMHCII-CD4 macrocomplex.
RESULTS
CD4 Enhances Functional Responses to Low-Affinity pMHCII
This study was designed to evaluate the interplay between the TCR-CD3 complex and CD4 by testing predictions made by the V-like arch and compact macrocomplex models ( Figure S1A ). We primarily used the archetypal cytochrome-c-reactive 5c.c7 TCR since there is a wealth of kinetic and functional data for 5c.c7 interactions with the moth cytochrome-c-derived agonist peptide presented within the mouse MHCII I-E k (dissociation constant [K D ] reported at 22.9-43.5 mM), the weak agonist T102S peptide (K D = 206 mM; $4-fold lower potency), and the immeasurably weak antagonist T102G peptide Gottschalk et al., 2010; Huppa et al., 2010) .
Prior to testing the models, we functionally characterized CD4. In vitro 5c.c7
+ CD4 + T cell responses mirror their in vivo responses to MCC and T102S Figure S1B ). Anti-CD4 reduced responses to MCC and eliminated responses to T102S, while no responses were observed to T102G ( Figure 1A ). We also evaluated CD69 expression and apoptosis of 5c.c7 + CD4 + CD8 -Tg thymocytes in vitro as they are more sensitive to low-affinity ligands. Anti-CD4 reduced responses to T102S as well as T102G ( Figures 1B, S1C , and S1D). Moving to more reductionist systems, we evaluated interleukin-2 (IL-2) production by 5c.c7
hybridomas. Anti-CD4 eliminated responses to MCC and T102S for CD4 + cells, while CD8 + (no CD4) cells did not respond (Figure 1C) . These data show that CD4 increases signaling by the 5c.c7 TCR in primary cells and T cell hybridomas responding to agonist and weak pMHCII.
Since the frequency of CD4:Lck association influences TCR signaling (Stepanek et al., 2014) , we also asked how a CD4-Lck fusion influences the perceived potency of MCC, T102S, and T102G. Previously, we reported that 5c.c7 + CD4-Lck + 58a -b -cells make IL-2 in response to M12 cells expressing tethered pMHCII with an unexpected hierarchy of T102G > T102S > MCC and also respond to null peptides in a manner that depended on high levels of pMHCII . Here, analysis of IL-2 production in response to a peptide titration showed the proper hierarchy of potency (MCC > T102S > T102G), but T102G elicited a greater response than T102S and MCC at the highest peptide concentration ( Figure 1D ). A small amount of IL-2 was also produced without exogenous peptides, consistent with intrinsic TCR scanning of MHCII . Expression of a CD4-Lck mutated in the D1 domain (CD4T Dbind -Lck), where crystal structures show CD4-MHCII interactions and which impairs an ordered spatial relationship between CD4 and the TCR-CD3 subunits upon TCR engagement Wang et al., 2001a) , did not facilitate IL-2 production to any of the peptides, so overexpression of Lck did not account for our results.
Since CD4:Lck interactions are not essential for CD4 function, we also interrogated how CD4-MHCII interactions impact TCR signaling in the absence of direct CD4:Lck interactions (Killeen and Littman, 1993; Parrish et al., 2016) . We used C-terminally truncated CD4 (CD4T), which lacks the cysteine clasp that mediates CD4:Lck interactions but nevertheless enhances IL-2 production by 5c.c7 + CD4T + 58a
b -T cell hybridomas to $60%-80% of levels observed with cells expressing full-length CD4, depending on the pMHCII density, and >10-fold relative to cells lacking CD4 . With CD4T, intracellular Lck is available to phosphorylate ITAMs but cannot directly tether CD4 to a TCR-CD3-pMHC unit via interactions with the CD3ε proline rich sequence (PRS), the CD3ε basic rich sequence (BRS), or with phosphorylated ITAMs via its SH2 domain (Li et al., 2017; Mingueneau et al., 2008; Xu and Littman, 1993) . CD4T was required for IL-2 production in response to MCC and T102S, when compared with CD4T Dbind ( Figure 1E ). CD4-MHCII interactions via the D1 domain thus impact the perceived potency of a pMHCII even when CD4 cannot directly interact with Lck.
Finally, we asked whether CD4T binds to the same pMHCII as the TCR to elicit IL-2 production, as indicated by previous studies of MHCI or MHCII mutants that impair CD8 or CD4 function, respectively (Connolly et al., 1990; Krogsgaard et al., 2005) . M12 cells were transduced with I-E k or an I-E k.E164A+T167A mutant that impairs CD4T function, along with tethered OVA:I-A b that has an intact CD4 binding site but cannot present the MCC peptide ( Figure S1E ) (Kö nig et al., 1992; Krogsgaard et al., 2005) . Consistent with prior results, the mutants impaired IL-2 production by 5c.c7 + CD4T + 58a
b -T cell hybridomas in response to MCC and T102S, providing additional evidence that CD4T binds the same pMHCII as the TCR ( Figure 1F ). (Figures 2A, 2B , S2A, and S2B) (Bain et al., 2007) .
CD4 Increases TCR-Mediated Cell Coupling
To further investigate whether the TCR and CD4 mediate coupling on their own we tested (1) whether TCR-pMHCII interactions mediate cell coupling in the absence of signaling or other TCR engagement-associated events (e.g., Nck or Lck interactions with the CD3ε PRS or basic rich sequences) (Gil et al., 2002; Li et al., 2017; Mingueneau et al., 2008; Xu and Littman, 1993) ; and (2) whether CD4T contributes to cell coupling. The 5c.c7 TCR was expressed with truncated CD3 subunits (CD3T) that lack their intracellular domains, and either CD4T or CD4T
Dbind on M12 cells, while our panel of tethered pMHCII were expressed on 58a -b -cells ( Figure S2C ). Again, the frequency of couple formation followed the expected hierarchy (MCC > T102S > T102G > Hb). MCC-driven coupling was not increased by CD4T relative to CD4T
Dbind
, and neither CD4T nor CD4T
Dbind cells coupled to Hb APCs even with high expression of pMHCII ( Figures 2C, S2C , and S2D). 5c.c7 interactions with T102S:I-E k were sufficient to mediate coupling (CD4T Dbind cells) and CD4T increased these interactions . Finally, the affinity of 5c.c7 for T102G:I-E k was too weak to mediate cell coupling by CD4T
Dbind cells, yet when combined with CD4-MHCII interactions cell coupling was achieved. These data show that CD4 can enhance cell coupling mediated by low-affinity TCR-pMHCII interactions at high pMHCII density.
To test whether CD4T impacts coupling with different TCR-pMHCII pairings, we used the 2B4, B3K506, and B3K508 TCRs in the same experimental setup. 2B4 is unique as it lacks five of the eight features typical of cytochrome-reactive TCRs, like 5c.c7, has higher affinity for MCC and T102S (K D z5.5-8.7 Figure S1 .
and 33.8-90 mM, respectively) and drives distinct effector differentiation (Fazilleau et al., 2009; Krogsgaard et al., 2003; Newell et al., 2011; Wu et al., 2002) . CD4T increased 2B4-mediated coupling to T102S, and more so to T102G, but not to MCC (Figure 2D ), indicating again that CD4 contributes to coupling when TCR-pMHCII affinity falls below some threshold (>33-90 mM).
The B3K506 TCR binds the 3K, P5R, and P-1A peptide in I-A b with affinities above this mark (K D = 7, 11, and 26 mM, respectively), while the B3K508 TCR binds the same pMHCII with a broader range of affinities (29, 93 , and >550 mM, respectively), allowing us to further test this idea (Govern et al., 2010) . CD4T did not increase cell coupling driven by B3K506 for any peptides I-E k+ 58α but increased B3K508-mediated coupling to P5R and P-1A ( Figures 2E, 2F , and S2E); further demonstrating that CD4 can contribute to cell coupling for lower-affinity TCR-pMHCII interactions. These results could reflect an additive contribution to adhesion if CD4 and the TCR bind pMHCII independently in a V-like arch, although a CD4-MHCII K D >2.5 mM makes this remote. Alternatively, they could reflect a cooperative effect similar to that described for some cytokine receptors and expected in a compact macrocomplex (Spangler et al., 2015) .
CD4 Increases TCR Adhesion to pMHCII In Situ
To further analyze CD4's impact on TCR-pMHCII interactions, we asked whether CD4T increased TCR-CD3T G accumulation on glass coverslips coated with pMHCII monomers relative to CD4T Dbind . Bright-field microscopy of 5c.c7 + CD3T + CD4T + M12 cells allowed an unbiased survey of all cells in the field, while TCR-CD3T G intensity was measured by live total internal reflection fluorescence microscopy (TIRFM) for a region of interest (ROI) across the widest point of contact ( Figure 2G ). CD4T
Dbind was used instead of anti-CD4 since prior studies of 5c.c7-MCC:I-E k interactions in situ reported a slight decline in TCR dwell time with anti-CD4, and one reported a reduction in the total number of TCR-pMHC interactions per cell that was attributed to interference from the antibody O'Donoghue et al., 2013) . Both 5c.c7 + CD3T + CD4T + and CD4T Dbind+ cells had TCR-CD3T G intensity that was proportional to the affinity of TCRpMHCII interactions (MCC > T102S > T102G > Hb) ( Figure 2H ). But CD4T dramatically enhanced the intensity on the T102S and T102G surfaces compared to CD4T
Dbind . These data indicate that CD4-MHCII interactions enhance weak TCR-pMHCII interactions. Similar results were observed with 2B4 + CD3T + CD4T + and CD4T Dbind+ M12 cells ( Figure 2I ). To establish the system, we calculated the mobile fraction and t 1/2 of recovery of 5c.c7-CD3T G molecules as they exchanged in and out of a bleached ROI on cells bound to surfaces coated with pMHCII of increasing affinity (Figures 3A-3C; Movies S1 and S2) (Klammt et al., 2015) . This movement would be a measure of on and off rates as well as surface mobility. Surface plasmon resonance (SPR) cannot detect 5c.c7 interactions with T102G:I-E k , but FRAP showed an increase in TCR-CD3T G t 1/2 on the T102G surfaces compared with Hb surfaces that increased further on the T102S and MCC surfaces. The near lack of mobility observed on MCC surfaces showed that rebinding impacts TCR-CD3T G confinement in the bleached area as the t 1/2 for a 5c.c7 TCR bound to MCC:I-E k at 37 C is 2.28 s . These data establish that TCR-CD3T G dwell time measured by FRAP follows the expected hierarchy. Next, we asked whether TCR-pMHCII affinity does or does not impact CD4T mobility in situ, as predicted by the compact or V-like macrocomplex models, respectively ( Figures 3D-3F ). While the mobile fraction was minimally impacted by changes in TCR-pMHCII affinity, the CD4T mCh t 1/2 increased proportionally to the affinity of TCR-pMHCII interactions on 5c.c7 To determine whether the observed differences in CD4T t 1/2 were due to direct interactions versus TCR-CD3 crowding, we compared CD4T mCh and CD4T Dbind.mCh mobility on 5c.c7 cells adhered to MCC:I-E k where CD4T did not increase TCR-CD3T G intensity ( Figure 2H Dbind.mCh intensity were equivalent, we observed a small difference in mobile fraction but not t 1/2 ( Figures 4C, 4D , and S4D-S4F). We also pairwise-matched 5c.c7 cells with TCR-CD3T G intensities that varied by less than 5% on T102S and MCC to compare CD4T dwell times under conditions of equivalent TCR-CD3 crowding and intact CD4-MHCII interactions (Figures 4E and 4F) . Here, the CD4T mCh t 1/2 was longer on the MCC surface than the T102S surface, while the mobile fraction was equivalent, indicating that TCR-pMHCII dwell time impacts CD4T-pMHCII dwell time (Figures 4G, 4H, and S4G) . CD4T mobility is therefore sensitive to TCR-pMHCII interactions. Finally, if TCR and CD4 bind pMHCII independently in a V-like arch, then CD4 t 1/2 should not be impacted by the quality of peptides presented therein, but the peptide sequence would impact the CD4 t 1/2 in a compact macrocomplex. For S5B ). As our initial analysis suggested that TCR rebinding on the high density MCC surface impeded TCR-CD3T G mobility, we also analyzed TCR-CD3T G mobility on surfaces with 12.5% MCC:I-E k diluted into Hb:I-E k . Here, the presence of CD4T slightly reduced the mobile fraction but dramatically increased the TCR-CD3T G t 1/2 compared to CD4T Dbind for both the 5c.c7 and 2B4 TCRs ( Figures 5A-5D , S5C, and S5D), showing the CD4T can increase TCR dwell time on low ligand densities of agonist pMHCII. To ask whether CD4T impacts TCR dwell times on lower-affinity ligands we monitored TCR-CD3T G mobility on T102S surfaces. Again, CD4T reduced the mobile fraction and increased TCR-CD3T G t 1/2 compared to CD4T Dbind for both the 5c.c7 and 2B4 TCRs (Figures 5E-5H, S5E, and S5F). These data are most consistent with a compact macrocomplex.
Mutations in the CD4 D3 Domain Impair Function A final difference between the V-like and compact macrocomplex models is that the former dictates that CD4 only binds MHCII via the D1 domain, while the latter predicts that CD4 contacts the TCR-CD3-pMHCII axis along its length. Our CD4 Dbind mutant provides evidence for the importance of the D1 domain, but to further test these models required mutants in an MHCIIdistal region of CD4.
Prior studies proposed that the D3 domain surface interacts with the TCR-CD3 complex, as mutating F208 and F227 (using UniProt convention) that extend into the CD4 D3 domain hydrophobic core impair signaling ( Figure S6A ) (Vignali and Vignali, 1999) . Since the cavity created by F208A and F227A could destabilize the D3 domain surface, we examined the surface above F208 and F227 and found that P228 and F231, as well as P281 on an adjacent loop, constitute a conserved nonpolar patch that borders a hydrophobic pocket (Figures S6A and S6B) . Such patches can mediate protein:protein interactions (DeLano et al., 2000) , leading us to ask whether changing the nature of this surface by mutagenesis (CD4T P228E+F231E and CD4T P281E ) would reduce its contribution to TCR signaling, proximity to the TCR-CD3 complex, and CD4 mobility upon pMHCII engagement. Glutamate was used to impart a negative charge on this surface, while mutating the rigid prolines was also likely to impact the shape, mobility, or surface stability (Wang et al., 2009) . Indeed, for P281 that facilitates a turn on one side of the nonpolar patch, the CD4T P281E mutant had slightly reduced cell-surface expression and increased Figure S6F ), CD4T P281E cells also made less IL-2 upon TCR engagement than the CD4T cells ( Figure 6D ). Since sorting requires coating cells with mAbs to CD4, which could deliver a signal and impact the responsiveness of cells that expanded thereafter, we used unsorted cells for our analysis of TCR downregulation and CD69 expression as flow cytometry allowed us to directly compare matched subsets by gating on equivalent CD4 expression ( Figure S6G ). Here, again we observed reduced responses by the CD4T P281E cells relative to the CD4T cells for multiple independently generated sets of lines (Figures 6E and 6F) .
As a final functional assay, we made 5c.c7 + 58a
b -cells expressing a CD4-Lck fusion, CD4T P228E+F231E -Lck, or CD4 DbindLck since we have reported that 5c.c7 + CD4-Lck + 58a
b -cells make IL-2 in response to high expression levels of MHCII presenting ''shaved'' peptides with alanine substitutions in the TCR contact residues . Our prior data suggest that the TCR and CD4 constantly work together to scan the peptide content of MHCII, so we reasoned that the CD4 P228E+F231E should have a profound impact on TCR scanning if the macrocomplex model has merit. Indeed, for CD4-Lck and CD4 P228E+F231E -Lck cells with equivalent expression, the mutation nearly ablated IL-2 production in response to the shaved MCC4A peptide in I-E k or the shaved 2W4A peptide in I-A b , while the CD4 Dbind -Lck cells had no response ( Figures  6G, 6H, and S6H ). Figure 7A ).
D3 Domain Mutants
Since CD4 is closer to the CD3 subunits than predicted by a V-like arch as described previously . Without pMHCII, CD3dT G ::CD4T mCh FRET E was indistinguishable between the cell lines ( Figure S7C ), but on immobile MCC surfaces the CD4T P228E+F231E , CD4T P281E and CD4T Dbind cells showed reductions in FRET E compared with the CD4T cells ( Figure 7B ). The CD4T P228E+F231E cells indicate that the D3 domain is important for increasing the frequency of CD4 and TCR-CD3 complexes that come into close association upon interactions with agonist pMHCII. The CD4T P281E cells support this conclusion, although their tendency to aggregate ( Figure S6C ) means that fewer CD4T P281E molecules may be available to interact with the TCR-CD3 complex. Finally, we used FRAP to determine how the CD4 mutants impact the kinetics of macrocomplex formation on immobile MCC:I-E k surfaces since the higher-affinity TCR-pMHCII interactions should provide the highest resolving power. While the D3 domain mutations did not impact the mobile fraction, the hierarchy of t 1/2 (CD4T > CD4T P228E+F231E > CD4T P281E > CD4T Dbind ) mirrored the FRET E results ( Figures 7C, S7H , and S7I).
These data further indicate that the D3 domain of CD4 is involved in the formation and stabilization of the TCR-CD3-pMHC-CD4 macrocomplex, albeit the same caveat holds for the CD4T P281E result here as above. Whether the CD4T P228E+F231E mutations disrupted interactions between CD4 and the TCR-CD3-pMHC axis mediated by the native residues, or induced allosteric changes in residues that mediate interactions cannot be known from the data provided here. The D3 hydrophobic core was not altered, so any allosteric changes should be localized to adjacent residues rather than propagated to a distant site. Altogether, the results suggest that the conserved nonpolar patch or proximal residues are involved in macrocomplex assembly and function.
DISCUSSION
CD4 has long been enigmatic. Originally, it was viewed as an accessory molecule until antibody-crosslinking experiments were interpreted to mean that the TCR and CD4 physically interact; the term coreceptor was then offered to define CD4 as a component of a multi-subunit receptor complex for pMHCII in order to distinguish it from a subsidiary function such as adhesion (Janeway, 1988) . Mutagenesis data were subsequently taken as evidence for TCR-CD4 interactions (Vignali et al., 1996; Vignali and Vignali, 1999) . However, the V-like crystal structures altered this thinking since the TCR and CD4 would not directly interact (Wang et al., 2001a; Yin et al., 2012) . A model that could reconcile these discordant results was proposed whereby the TCR-CD3 complex pre-associates with the CD4 D3 and D4 domains and crosslinks one TCR-pMHCII assembly to another (Irvine et al., 2002; Krogsgaard et al., 2005) . But recent FRET and super-resolution data show that the TCR-CD3 complex and CD4 do not pre-associate in the absence of coincident pMHCII engagement or adopt the spatial relationship predicted by that model Roh et al., 2015) . Thus, fundamental questions persist regarding how CD4 fits and works within this multi-subunit molecular machine. The data presented here do not conform with expectations regarding how the TCR and CD4 should behave if they were to bind pMHCII in a V-like arch, but they are consistent with pMHCII receptor signaling having converged on a mechanism akin to cytokine signaling (Kuhns and Badgandi, 2012; Madrenas et al., 1997) . For example, binding of the cytokine-specific IL-4Ra subunit to IL-4 forms a composite docking interface to which the degenerate gc subunit binds with a higher affinity than to IL-4 alone; only then are the IL-4Ra and gc-associated Janus Kinases positioned in a spatial and temporal relationship that facilitates signaling (Wang et al., 2009) . By analogy, our data are consistent with the TCR-CD3 complex serving as a specific receptor subunit for pMHCII, while CD4 represents a degenerate subunit with no appreciable affinity for pMHCII on its own. In this scenario, the constrained docking polarity observed for TCRs on pMHCII (Rossjohn et al., 2015) results in a highly reproducible composite surface along the TCR-CD3-pMHCII axis to which CD4 would bind with higher affinity than to MHCII alone. Docking would then position Lck in the proper spatial and temporal relationship with the CD3 ITAMs to allow for phosphorylation.
The most straightforward extracellular docking topology would follow an apparent shape complementarity between CD4 and the TCR-CD3-pMHCII axis ( Figure S1A ) since (1) structural data indicate that large-scale conformational changes in the TCR or CD3 ectodomains do not occur upon pMHCII or mitogenic mAb engagement; (2) experimental data point to a stable TCR-CD3 unit bound by continuous interactions between the ecto and transmembrane domains; and (3) FRET analysis indicate that CD4 is proximal to CD3d (Call et al., 2002; Ding et al., 1999; Fernandes et al., 2012; Garcia et al., 1999; Glassman et al., 2016; Kuhns and Badgandi, 2012; Kuhns and Davis, 2007; Kuhns et al., 2010; Sun et al., 2001; Xu et al., 2006 ). An alternative hypothesis, akin to the permissive geometry model, is that TCR engagement moves the CD3 ectodomains to expose a CD4 contact site on the TCR (Minguet et al., 2007) . Either way, initial CD4-MHCII interactions could allow a pivot from a V-like arch to a lower energy docked position via a ball-and-socket movement akin to the V H -C H elbow of antibodies (Lesk and Chothia, 1988) . Or, docking may occur straight away. Importantly, once docked, an additional anchor could form via intracellular interactions between Lck and the CD3 subunits (Li et al., 2017; Mingueneau et al., 2008; Xu and Littman, 1993) .
Prior studies suggest that macrocomplexes form constantly, regardless of the peptide content of an MHCII, can signal in response to very weak ligands on thymocytes and that both the TCR-pMHCII dwell time and the frequency of CD4-Lck interactions influence the signaling outcome (Kao and Allen, 2005; Parrish et al., 2016; Stepanek et al., 2014; Wang et al., 2001b) . Here and elsewhere, CD4 minimally impacted agonist TCR-pMHCII interactions if only agonist pMHCII is present, indicating there is a TCR dwell time above which CD4 is more likely to cycle through these macrocomplexes than enhance TCRpMHCII dwell time (Crawford et al., 1998; Hong et al., 2015; Huppa et al., 2010; O'Donoghue et al., 2013; Stepanek et al., 2014; Wooldridge et al., 2006) . However, CD4 did influence TCR dwell time on agonist ligands diluted among null ligandsconditions that were not explored in prior studies-suggesting that CD4 can make a relevant contribution to TCR dwell time on agonist pMHCII. Our data also demonstrate that CD4 increases TCR dwell time on low-affinity pMHCII. These results are consistent with biomembrane force probe (BFP) 2D affinity measurements of the 3.L2 TCR that showed no contribution of CD4 to the agonist Hb:I-E k pMHCII, but a significant contribution to binding of an antagonist (I72) pMHCII and a trend toward significance with a weak agonist ligand (T72; p = 0.06) (Hong et al., 2015) . Importantly, we found the CD4 dwell time on pMHCII to be proportional to that of the TCR in a bulk assay, yet the CD4 t 1/2 was always faster than the TCR; therefore, the kinetics of TCRpMHCII interactions would influence the duration that a docking interface remains intact for CD4 molecules to cycle through in a processive-like manner (Stepanek et al., 2014) . By increasing TCR-CD3 dwell time on lower-affinity pMHCII, CD4 might help recruit a greater breadth of clonotypes from the CD4 + T cell repertoire that differentiate to distinct effector phenotypes Tubo et al., 2013) . This also appears likely to be key for signaling in response to the weak TCR-pMHCII interactions that drive CD4 + T cell development and homeostasis (Kao and Allen, 2005; Parrish et al., 2016; Stepanek et al., 2014; Wang et al., 2001b) . A final implication of this macrocomplex design is that it provides an explanation for how distinct constituents of the TCR repertoire can reproducibly direct the appropriate response to an immunological challenge. At issue is that if TCRs bind pMHCII in a noncanonical orientation, then the docking interface for CD4 would not be formed and any recruitment of Lck to the ITAMs by CD4 would be subject to the problems outlined above for a V-like arch with extraordinarily weak CD4-MHCII interactions. So, if two TCRs interact with the same pMHCII via the same kinetic properties but different docking modalities, then they would likely produce very different outcomes due to differences in both the spatial relationship between Lck and the ITAMs, and the duration with which they are held there. But it is now clear that there is a reliable relationship between the kinetics of TCR-pMHCII interactions and CD4 + T cell signaling, gene expression, and effector functions (Allison et al., 2016; Corse et al., 2010; Gottschalk et al., 2010; Govern et al., 2010; Kersh et al., 1998; Stepanek et al., 2014; Tubo et al., 2013; van Panhuys et al., 2014; Vanguri et al., 2013) . Since the highly ordered macrocomplex imposes uniform requirements for assembly on a diverse collection of TCRs within the repertoire, the spatial relationship between Lck and each of the ten ITAMs will always be the same for any TCR that docks appropriately, as supported by our recent FRET analysis . Consequently, the quantity and quality of ITAM phosphorylation by CD4-associated Lck would be determined strictly by the kinetic factors that influence the stability of the macrocomplex, and thus the duration of Lck proximity to any given ITAM, as suggested previously (Kersh et al., 1998) . We thus postulate that the precise assembly of this molecular machine has evolved as an equalizer that ensures a reproducible translation of information, regarding specificity at the TCR-pMHCII interface, into scalable signaling at the ITAMs; in turn, the extent of ITAM phosphorylation would determine CD4 + T cell responses (Guy et al., 2013; Holst et al., 2008; Hwang et al., 2015) . Future experiments will be required to interrogate how these molecular mechanisms influence cell-fate decisions in vivo.
EXPERIMENTAL PROCEDURES
Cell lines, constructs, standard experimental procedures, and previously described image acquisition and analysis can be found in Supplemental Experimental Procedures.
Mice 6-to 8-week-old male and female 5c.c7 TCR Tg mice were used for spleenocyte and thymocyte co-cultures. Mice were maintained under specific pathogen-free conditions in the University of Arizona animal facility. Experiments were conducted under the guidelines and approval of the University of Arizona Institutional Animal Care and Use Committee.
Image Analysis
For subunit accumulation, cells were bisected with a line scan ROI in bright field, and the median mEGFP intensity was exported using SlideBook6 (3I). Data were imported into Prism (GraphPad) and displayed as fluorescence intensity.
FRAP analysis was performed as described (Klammt et al., 2015) . Background subtracted median fluorescence intensity in the photobleached regions and a 6.45-mm 2 photobleach control region were exported for analysis in MATLAB (MathWorks). Photoablation was calculated as the ratio of postbleach to prebleach fluorescence intensity, Abl = I t = 0 /I t = À1 where t = À1 is the time point prior to bleaching and t = 0 is first frame postbleach. Analyzed events had photobleaching to <20% of prebleach intensity. Recovery (%) was computed for each time point (t = x) as Recovery = (I t = x ÀI t = 0 )/ (I t = À1 ÀI t = 0 )*100 where t = À1 is the time point prior to bleaching and t = 0 is first frame postbleach. FRAP data were fitted with a single-term exponential function, F = A(1-e -kt ) where F is fluorescence intensity, A is the mobile fraction, t is the elapsed time following photobleaching and k is related to the half-life such that t 1/2 = ln(2)/k.
Statistical Analysis
Statistical analyses were performed using Prism 6 (GraphPad software) and are indicated in the figure legends along with sample size (n). Data were assessed for normality using a D'Agostino and Pearson omnibus normality test. Data that were normally distributed were further analyzed using a one-way analysis of variance (ANOVA) and Dunnet's multiple comparison test or a t test, as indicated in the figure legends. Nonparametric data were analyzed using a Mann-Whitney test. For FRAP analysis, fit and 95% confidence intervals (CIs) were generated using MATLAB nonlinear fitting (Klammt et al., 2015) .
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, seven figures, and two movies and can be found with this article online at https://doi.org/10.1016/j.celrep.2017.12.104.
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Cell lines and constructs
58α
-β -and M12 cells were generated by retroviral transduction using the MSCV-based retroviral expression vectors pP2 (IRES-puromycin resistance) and pZ4 (IRES-zeocin resistance) Lee et al., 2015; Parrish et al., 2016) .
Proteins encoded by the constructs used in this study are described by amino acid (aa) number beginning at the start methionine (UniProt convention). Constructs encoding cDNA for the B3K506 and B3K508 TCRs were kindly provided by Eric Huseby and used for PCR amplification for cloning into pP2 (TCRβ) and pZ4 (TCRα). The 5c.c7 or 2B4 TCR, which are specific for moth cytochrome c (88-103) presented in I-E k , or the B3K506 or B3K508
TCRs specific for the 3K peptide presented in I-A b were expressed with full length or C-terminally truncated CD3
subunits (CD3δT aa:1-132, CD3γT aa:1-143, CD3εT aa:1-139, and CD3ζT aa:1-57) along with a C-terminally truncated CD4 (CD4T aa:1-421) . CD4T variants used in this study were CD4T Δbind (aa: 68-73
KGVLIR to DGDSDS), CD4T
P228E+F231E and CD4T
P281E
.
For 58α -β -lines, the C-terminus of the 5c.c7 α chain, 2B4 β chain, B3K506 β chain or B3K508 β chain was fused to mEGFP via a long flexible linker (AAAGGGGSGGGGSGGGGS), the 5c.c7 β chain, 2B4 α chain, B3K506 α chain, B3K508 α chain and CD4T were encoded by independent constructs and full-length CD3 subunits were encoded by a poly-cistronic construct as previously described Parrish et al., 2016) .
5c.c7 + M12 lines were generated using constructs encoding CD3εT-T2A-5c.c7α, CD3ζT-T2A-5c.c7β, CD3δT G -T2A-CD3γT and CD4T mCh . CD3δT was fused to mEGFP via a flexible GGSAAG linker and CD4 was fused to mCherry via an AAAG linker as previously described . CD3ζT was fused via a GGSAAG linker to the biotin acceptor peptide, AP-3, a short tag that was considered irrelevant for the current study.
2B4
+ M12 lines were generated using constructs encoding 2B4α, 2B4β G , CD4T mCh , and a polycystronic construct encoding C-terminally truncated CD3 subunits. The 2B4 β chain was fused to mEGFP via a long flexible linker (AAAGGGGSGGGGSGGGGS) and CD4 was fused to mCherry via an AAAG linker as previously described .
APCs were generated by transducing M12 or 58α -β -cells with full-length I-E k α or I-A b α and full-length I-E k β or I-A b β fused via the N-terminus to a peptide as previously described Parrish et al., 2015) .
Peptides bound to I-E k in this study were moth cytochrome c (MCC 88-103), the altered peptide ligands T102S and T102G, and the mouse hemoglobin d allele . Peptides bound to I-A b in this study were Ova 326-338, 3K
and the altered peptide ligands P-1A and P5R (Huseby et al., 2006) .
Cell surface expression of CD4 (mAb clone GK1.5 e450 eBioscience), TCRα (Vα11, mAb clone RR8-1 allophycocyanin eBioscience), TCRβ (Vβ3, mAb clone KJ25 PE BD Biosciences), I-E k (mAb clone 14-4-4S) and I-A b (mAb clone KH74) were determined by flow cytometry as indicated in the figures. The P281E mutation reduced cell surface expression on 58α -β -cells, so lines were FACS sorted using a non-blocking CD4 antibody (mAb clone RM4-4 PE Biolegend).
Functional assays
For peptide titration experiments, 5 X 10 4 5c.c7 TCR transgenic spleenocytes or thymocytes or 5 X 10 4 58α -β -cells
were co-cultured with 1 X 10 5 M12 I-E k cells and MCC 88-103, T102S, or T102G peptide at the indicated concentration in 96-well round-bottom plates and peptides were purchased at ninety percent purity from 21 st Century Biochemicals, Inc. In indicated experiments, anti-CD4 (mAb clone GK1.5) or anti-CD8 (control, mAb clone 53.6-7)
was added at 20μg/mL. Supernatants were harvested for IL-2 ELISA after 16 hours co-culture as described below.
Thymocyte co-cultures were incubated for 14 hours at 37°C and stained for Vα11 (mAb clone RR8-1, APC, 
Soluble proteins for bilayers and immobile surfaces
ICAM-1 and pMHCII production were described previously .
Lipid bilayers
Unilaminar vesicles were generated by extruding a lipid mixture consisting of 97.5mol % POPC, 1 mol % DGS NiNTA, 1 mol biotin-CAP PE and 0.5 mol % DOPE-PEG5000 (Avanti Polar Lipids) .
Bilayers were formed on cleaned glass coverslips and functionalized with 0.05 µg/well MCC:I-E k and 0.08µg/well ICAM-1 to give a pMHCII density of ~60molecules/µm 2 .
Immobile surfaces
Biotinylated poly-L-lysine coated coverslips were coated with 5µg/mL streptavidin, washed and incubated with 5µg/mL pMHCII biotin plus 0.5µg/mL biotinylated anti H2-D d , which was used to ensure cell attachment Huse et al., 2007) .
Microscopy
Total internal reflection fluorescence microscopy (TIRFM) was performed as previously described . In brief, cells were allowed to interact with the imaging surface for 20' prior and then imaged for 20-30'.
Data were collected with a Marianas workstation built on a Zeiss Axio Observer Z1 (Intelligent Imaging
Innovations, 3I) using a 63x Zeiss TIRF objective coupled to a Zeiss motorized TIRF slider (numerical aperture 1.46). Illumination was achieved with a Laser Stack (3I) containing 50mW 488nm and 561 solid-state lasers at 20%
output. Photoablation was performed using a Vector high-speed point scanner (3I) at 100% laser power within a 6.45μm 2 region of interest (ROI) and images were collected using a Photometrics Evolve EMCCD camera (1 pixel= 0.25μm (H) x 0.25μm (V)). Receptor accumulation images consisted of TIRF and brightfield images collected at a single time point. For Fluorescence Recovery After Photobleaching (FRAP) acquisitions, fluorescence images were acquired at 3 sec intervals. Donor Recovery after Acceptor Photobleaching images were acquired at 500ms intervals.
FRET E analysis
Donor Recovery after Acceptor Photobleaching was performed as previously described .
Analyzed cells had bleaching below 12.5% of prebleach mCherry intensity. Subsets were matched for mCherry intensity, mEGFP intensity (postbleach) and mEGFP/mCherry ratio in TIRF. FRET efficiency (FRET E ) was calculated using: FRET E = 1 -Q/DQ where Q is the mEGFP intensity prior to photobleaching and DQ is the mEGFP intensity following mCherry ablation. (1) The unengaged TCR-CD3 complex is shown with CD3ε and CD3ζζ ITAMs associated with the inner leaf of the T cell membrane (Aivazian and Stern, 2000; Shi et al., 2013; Xu et al., 2008) . CD4 is shown associated with an active Lck on a T cell surface (upper blue sphere) (Nika et al., 2010) . The surface of an APC (lower blue sphere) is shown with a pMHCII.
(2) The V-like arch model is shown as possible intermediate in the formation of a compact macrocomplex (Wang et al., 2001; Yin et al., 2012) . The solution K d are noted for CD4-MHCII and agonist to weak agonist TCR-pMHCII interactions Jonsson et al., 2016) . the ITAMs are shown free of the membrane based on previous studies (Shi et al., 2013; Xu et al., 2008; Zhang et al., 2011) . (3) The final subunit assembly of a compact TCR-CD3-pMHCII-CD4 macrocomplex (Kuhns and Badgandi, 2012 % of max (A) A surface rendered structure of hCD4 (PDB: 1WIO) is shown in Salmon with the D1, D2, D3, and D4 domains labeled. The orange box around residues in the C-terminal D1 domain highlight the MHCII contact site identified in previous structural analysis (Wang et al., 2001; Yin et al., 2012) . Orange residues highlight those mutated for the Δbind mutant used in this study . The D3 domain solvent exposed residues P228 (purple), F231 (purple), and P281 residues (green) mutated in this study are shown along with the hydrophobic core residues F208 and F227 (yellow) that were previously studied (Vignali and Vignali, 1999) . The D3 domain is also shown as a cartoon structure to better highlight these colored residues (upper inset). The nonpolar patch created by P228, F231, and P281 is shown (lower inset) colored by atoms (carbon = yellow, hydrogen = grey, oxygen = red, nitrogen = blue). Images were generated with the PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC.
(B) Sequence alignment of the CD4 D3 domain residues targeted for mutagenesis. The mutants generated for this study are shown color-coded as in the structure. (C) Donor recovery after acceptor photobleaching of WT or mutant CD4 mCh ::CD4 GFP on glass coverslips (unengaged). Data are representative of three independent experiments and were assessed for normality using a D'Agostino and Pearson omnibus normality test followed by a one-way analysis of variance (ANOVA) and Dunnet's multiple comparison test (*p<0. CD4T mCh MCC I Figure S7 
